Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model.
about
Peripheral blood stem cell mobilization: new regimens, new cells, where do we standInfluence of a dual-injection regimen, plerixafor and CXCR4 on in utero hematopoietic stem cell transplantation and engraftment with use of the sheep model.Large animal models of hematopoietic stem cell gene therapy.Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation.Late infusion of cloned marrow fibroblasts stimulates endogenous recovery from radiation-induced lung injury.Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjectsHuman progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor.Potency analysis of cellular therapies: the emerging role of molecular assaysDifferentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis.Mobilization of hematopoietic stem/progenitor cells: general principles and molecular mechanisms.The central role of the chemokine receptor, CXCR4, in haemopoietic stem cell transplantation: will CXCR4 antagonists contribute to the treatment of blood disorders?Emerging hematological targets and therapy for cardiovascular disease: From bench to bedsidePlerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model.Delaying DLA-haploidentical hematopoietic cell transplantation after total body irradiation.In vivo protection of activated Tyr22-dihydrofolate reductase gene-modified canine T lymphocytes from methotrexate.Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.Novel agents and approaches for stem cell mobilization in normal donors and patients.Mechanisms of radiation-induced skin injury and implications for future clinical trials.Physiology and pharmacology of plerixafor.Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.Long-term Tolerance Toward Haploidentical Vascularized Composite Allograft Transplantation in a Canine Model Using Bone Marrow or Mobilized Stem Cells.Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.Plerixafor-moblized stem cells alone are capable of inducing early engraftment across the MHC-haploidentical canine barrier.Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest.CXCR₄antagonism as a therapeutic approach to prevent acute kidney injury.Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003.AMD3100 and CD26 modulate mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated by the SDF-1/CXCL12-CXCR4 axis.Collection of hematopoietic CD34 stem cells in rhesus macaques using Spectra Optia.
P2860
Q33589591-4E835416-8393-4F8D-A0C6-2B3567D579FBQ34038572-DF597F5B-C56D-429D-B192-899334B85FACQ34039922-D15981D2-71AD-4A3D-BAA4-274A569EFEF6Q34520475-EA044A0A-D0F5-481A-B687-E51FB2C6043DQ34631664-C4B838FE-A36C-40DF-B675-9AAD7C57E250Q35665207-A25F5C17-1393-4E64-9785-448D9491FB9CQ35793034-56D8AFB2-A1F1-4BCB-9F76-2A3CE63231DFQ35840586-71599E79-5189-45C8-9011-B38B47F43288Q36823321-40B2BB7C-D5D3-46EA-A338-3B0BCA99677DQ36912497-6165D34C-3D51-4931-873C-CFCD0EF9C307Q37016290-6E52C86B-B9FC-49BC-BEFE-22EC1C99969EQ37290687-2C7AD45D-C2BE-4C94-9A26-9422D4EC8C7CQ37352492-6F493AD2-2602-4BB5-8D8C-CC8F48894847Q37363004-DFAD5AC1-9517-4AC3-B7AC-901530AC12FFQ37375483-33653F20-CC32-4C67-8686-0BC009F2F84FQ37457900-C5236A25-1C39-49D6-A285-1BCF723A0AA6Q37921284-098924F5-337D-4740-AA7C-4A950BA7A58FQ37923309-2A9680CB-8888-46F6-B70D-F04767C9DBB0Q38072978-2C6BB5D7-2340-4EC4-92C0-0CD8687A0D4CQ38157897-14B92B30-F1F7-4BCA-8C7A-F897DEFEC65AQ38160461-39DFB02A-0CC6-4D87-8C69-052A0DA473F5Q39176265-5C67316B-65E5-40D7-8669-3962BD467E23Q39958361-4D86A921-8B79-461A-992D-8D2801599419Q42924622-870D1B40-7A5F-4901-9AB4-A6A1F58359ADQ44592988-1BD85F5C-E94C-42CB-893B-776D0A78EB82Q45419445-DCB61F8F-493B-42D7-9364-7699F6B022E5Q45868417-1354630F-349F-41A6-87F3-45395848A2E1Q53565993-38A2E37B-ACB9-4357-B65B-DC1534695C91Q54518187-F8D17181-57D9-4340-846E-B2C7894FAA45
P2860
Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Durable engraftment of AMD3100 ...... canine transplantation model.
@ast
Durable engraftment of AMD3100 ...... canine transplantation model.
@en
type
label
Durable engraftment of AMD3100 ...... canine transplantation model.
@ast
Durable engraftment of AMD3100 ...... canine transplantation model.
@en
prefLabel
Durable engraftment of AMD3100 ...... canine transplantation model.
@ast
Durable engraftment of AMD3100 ...... canine transplantation model.
@en
P2093
P2860
P50
P1433
P1476
Durable engraftment of AMD3100 ...... canine transplantation model.
@en
P2093
Gary Bridger
Jean Labrecque
Lauri Burroughs
Marie-Térèse Little
Ron Macfarland
Simon Fricker
P2860
P304
P356
10.1182/BLOOD-2005-05-1937
P407
P577
2005-08-16T00:00:00Z